Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 12/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471204 | 0.85 | USP30 (0.42) | USP30RETBRD4CREBBP | |
| SCHEMBL17673209 | 0.85 | USP30 (0.42) | USP30RETBRD4CREBBP | |
| SCHEMBL29471274 | 0.81 | USP30 (0.41) | USP30RET | |
| SCHEMBL26548299 | 0.81 | USP30 (0.41) | USP30RET | |
| SCHEMBL17799507 | 0.76 | USP30 (0.41) | USP30RETBRD4CREBBPPIK3CD | |
| SCHEMBL29471152 | 0.76 | USP30 (0.41) | USP30RETBRD4CREBBPPIK3CD | |
| SCHEMBL17785736 | 0.76 | USP30 (0.46) | USP30RET | |
| SCHEMBL17799535 | 0.75 | BRD4 (0.38) | USP30RETBRD4CREBBPTBK1 | |
| SCHEMBL24316708 | 0.75 | ROCK2 (0.39) | — | |
| SCHEMBL24316702 | 0.74 | RET (0.46) | USP30RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | USP30 1019/4885RET 2173/4885BRD4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.